138 related articles for article (PubMed ID: 24385223)
1. Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.
Sawaya R; Radwan W; Hammoud S
Med Oncol; 2014 Feb; 31(2):831. PubMed ID: 24385223
[No Abstract] [Full Text] [Related]
2. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
Abbas O; Shamseddin A; Temraz S; Haydar A
BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
[TBL] [Abstract][Full Text] [Related]
3. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
[No Abstract] [Full Text] [Related]
4. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
[No Abstract] [Full Text] [Related]
5. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
Peter S; Hausmann N; Schuster A; Boehm HF
Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
[No Abstract] [Full Text] [Related]
6. Posterior reversible encephalopathy syndrome with bevacizumab.
Lau PC; Paunipagar B
Hong Kong Med J; 2011 Feb; 17(1):80-1. PubMed ID: 21282833
[No Abstract] [Full Text] [Related]
7. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case.
Koopman M; Muller EW; Punt CJ
Dis Colon Rectum; 2008 Sep; 51(9):1425-6. PubMed ID: 18470563
[No Abstract] [Full Text] [Related]
8. Posterior reversible encephalopathy syndrome after bevacizumab treatment presenting to the ED as chest pain and headache.
Miller AH; Monteiro de Oliveira Novaes JA; Brock PA; Sandoval M
Am J Emerg Med; 2016 Sep; 34(9):1916.e1-2. PubMed ID: 26947375
[No Abstract] [Full Text] [Related]
9. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.
Seet RC; Rabinstein AA
QJM; 2012 Jan; 105(1):69-75. PubMed ID: 21865314
[TBL] [Abstract][Full Text] [Related]
10. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
J Ocul Pharmacol Ther; 2010 Jun; 26(3):301-3. PubMed ID: 20565319
[TBL] [Abstract][Full Text] [Related]
11. Voice disorders induced by bevacizumab administration in an ovarian cancer patient: an underestimated and rare toxicity.
Kountourakis P; Antoniou G; Papadimitriou K; Vassiliou V; Syrigos D; Philippou M; Papamichael D
Hematol Oncol Stem Cell Ther; 2014 Sep; 7(3):123-4. PubMed ID: 25066794
[No Abstract] [Full Text] [Related]
12. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
Wang W; Zhao LR; Lin XQ; Feng F
World J Gastroenterol; 2014 Jun; 20(21):6691-7. PubMed ID: 24914397
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Lou E; Turner S; Sumrall A; Reardon DA; Desjardins A; Peters KB; Sampson JH; Friedman HS; Vredenburgh JJ
J Clin Oncol; 2011 Oct; 29(28):e739-42. PubMed ID: 21900098
[No Abstract] [Full Text] [Related]
14. Bevacizumab and relapsed ovarian cancer: too many serious and life-threatening adverse effects.
Prescrire Int; 2013 Dec; 22(144):289. PubMed ID: 24600726
[TBL] [Abstract][Full Text] [Related]
15. Medication neurotoxicity in children.
Iyer RS; Chaturvedi A; Pruthi S; Khanna PC; Ishak GE
Pediatr Radiol; 2011 Nov; 41(11):1455-64. PubMed ID: 21785849
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib induced unilateral posterior reversible encephalopathy syndrome.
Arslan BM; Bajrami A; Demir E; Cabalar M; Yayla V
Ideggyogy Sz; 2017 Mar; 70(3-4):140-144. PubMed ID: 29870619
[TBL] [Abstract][Full Text] [Related]
17. Small reduction in quality of life seen with bevacizumab maintenance in patients with ovarian cancer.
Barton MK
CA Cancer J Clin; 2013; 63(4):219-20. PubMed ID: 23733586
[No Abstract] [Full Text] [Related]
18. Posterior reversible encephalopathy syndrome after long-term treatment with low-dose sunitinib: a case report.
Saraceno L; Ricigliano VAG; Cavalli M; Meola G
Neurol Sci; 2017 Jun; 38(6):1119-1121. PubMed ID: 28224329
[No Abstract] [Full Text] [Related]
19. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab.
Palma JA; Gomez-Ibañez A; Martin B; Urrestarazu E; Gil-Bazo I; Pastor MA
Neurologist; 2011 Sep; 17(5):273-5. PubMed ID: 21881470
[TBL] [Abstract][Full Text] [Related]
20. Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Chelis L; Souftas V; Amarantidis K; Xenidis N; Chamalidou E; Dimopoulos P; Michailidis P; Christakidis E; Prassopoulos P; Kakolyris S
BMC Cancer; 2012 Oct; 12():489. PubMed ID: 23088634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
